SITE006-0230

SITE006 (GBR) › SITE006-0230

SITE006-0230

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-06-04

completed

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 34); relationship: not assessed

moderate assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-23 (study day 17); relationship: not assessed

mild assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 6); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.